Breaking News Instant updates and real-time market news.

NBRV

Nabriva Therapeutics

$1.80

0.07 (4.05%)

07:05
01/14/19
01/14
07:05
01/14/19
07:05

Nabriva Therapeutics: FDA updates PDUFA date for Contepo NDA to April 30

Nabriva Therapeutics announced that the U.S. FDA has updated the PDUFA goal date for the completion of the FDA's review of the CONTEPO New Drug Application from June 30, 2019 to April 30, 2019. The two-month acceleration is due to a clarification of the classification and subsequent expedited review period for the CONTEPO NDA submitted in October 2018. In addition to priority review, CONTEPO has been granted Qualified Infectious Disease Product and Fast Track designations by the FDA for the treatment of several serious infections, including cUTI.

NBRV Nabriva Therapeutics
$1.80

0.07 (4.05%)

05/31/18
NORL
05/31/18
INITIATION
Target $17.5
NORL
Outperform
Nabriva Therapeutics initiated with an Outperform at Northland
Northland initiated Nabriva Therapeutics with an Outperform and $17.50 price target.
08/27/18
BOFA
08/27/18
NO CHANGE
Target $5
BOFA
Buy
Nabriva Therapeutics price target lowered to $5 from $9 at BofA/Merrill
BofA/Merrill analyst Jason Gerberry lowered his price target on Nabriva Therapeutics to $5, citing his lower expected probability of success of 60% vs. 75% prior in its recently acquired CONTEPO for complicated urinary tract infection. The analyst says the program's main risk is an "imbalance of liver enzyme elevation while a slightly higher dose reduces read -through from about a 45-year post-market EU safety". Gerberry now believes that CONTEPO is a "niche opportunity", and lowers his peak sales view to $50M from $80M prior. The analyst also keeps his Buy rating on Nabriva on valuation as well as the opportunity for its two FDA action dates for lefamulin and CONTEPO in the second half of 2019.
09/07/18
MSCO
09/07/18
INITIATION
Target $8
MSCO
Overweight
Nabriva Therapeutics resumed with an Overweight at Morgan Stanley
Morgan Stanley analyst David Lebowitz resumed coverage of Nabriva Therapeutics with an Overweight rating and a $8 price target, stating that its "first-in-class" antibiotics lefamulin and Contepo both have approvable Phase 3 data. He believes at current levels Nabriva shares are pricing in a "worst case scenario" for both antibiotics, but he sees it as likely that Nabriva exceeds the low expectations. Lebowitz forecasts risk-adjusted 2025 sales for lefamulin and Contepo of $228M and $33M, respectively.
11/14/18
RHCO
11/14/18
NO CHANGE
Target $11
RHCO
Buy
Nabriva Therapeutics price target lowered to $11 from $16 at SunTrust
SunTrust analyst Edward Nash lowered his price target on Nabriva Therapeutics to $11 after its Q3 earnings and the management's recent NDR presentation. The analyst says the company has disclosed that it has filed an NDA for Contepo in cUTI and plans to submit an NDA for lefamulin in community-acquired bacterial pneumonia with intention to price both drugs competitively to encourage their early use. Nash states that his lowered price target reflects the company's competitive pricing strategy but also keeps his Buy rating on Nabriva Therapeutics to reflect the potential of its treatments longer term.

TODAY'S FREE FLY STORIES

CRWS

Crown Crafts

$5.68

(0.00%)

09:38
01/21/19
01/21
09:38
01/21/19
09:38
Hot Stocks
Crown Crafts announces retirement of NoJo Baby & Kids CEO »

Crown Crafts (CRWS)…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

AL

Air Lease

$37.50

0.6 (1.63%)

, BA

Boeing

$364.79

5.52 (1.54%)

09:36
01/21/19
01/21
09:36
01/21/19
09:36
Hot Stocks
Air Lease announces lease placement of Boeing 737 MAX 9 »

Air Lease (AL) announced…

AL

Air Lease

$37.50

0.6 (1.63%)

BA

Boeing

$364.79

5.52 (1.54%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 30

    Jan

  • 21

    Feb

  • 28

    May

UTSI

UTStarcom

$3.22

0.1 (3.21%)

09:34
01/21/19
01/21
09:34
01/21/19
09:34
Hot Stocks
UTStarcom says TDI paid $4.54 per share to increase stake to 9.9% »

UTStarcom announced that…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

VRTX

Vertex

$194.63

4.19 (2.20%)

09:31
01/21/19
01/21
09:31
01/21/19
09:31
Hot Stocks
Vertex says European Commission granted label extension for Orkambi »

Vertex Pharmaceuticals…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 11

    Feb

ALNY

Alnylam

$83.08

2.4 (2.97%)

09:30
01/21/19
01/21
09:30
01/21/19
09:30
Hot Stocks
Alnylam, Israel's Medison partner to commercialize Onpattro, RNAi portfolio »

Alnylam Pharmaceuticals…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

THO

Thor Industries

$66.56

1.905 (2.95%)

09:26
01/21/19
01/21
09:26
01/21/19
09:26
Hot Stocks
Thor finalizing talks to exclude EHG's North American operations from deal »

Thor Industries provided…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

PLWTY

Panalpina

$0.00

(0.00%)

08:44
01/21/19
01/21
08:44
01/21/19
08:44
Downgrade
Panalpina rating change  »

Panalpina downgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

EFGSY

Eiffage

$0.00

(0.00%)

08:41
01/21/19
01/21
08:41
01/21/19
08:41
Upgrade
Eiffage rating change  »

Eiffage upgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

TVFCF

Television Francaise 1

$0.00

(0.00%)

08:40
01/21/19
01/21
08:40
01/21/19
08:40
Downgrade
Television Francaise 1 rating change  »

Television Francaise 1…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

ATVDY

Atresmedia

$0.00

(0.00%)

08:37
01/21/19
01/21
08:37
01/21/19
08:37
Upgrade
Atresmedia rating change  »

Atresmedia upgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

TDPAY

Tod's

$0.00

(0.00%)

08:36
01/21/19
01/21
08:36
01/21/19
08:36
Downgrade
Tod's rating change  »

Tod's downgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

SFRGY

Salvatore Ferragamo

$0.00

(0.00%)

08:35
01/21/19
01/21
08:35
01/21/19
08:35
Downgrade
Salvatore Ferragamo rating change  »

Salvatore Ferragamo…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

08:35
01/21/19
01/21
08:35
01/21/19
08:35
General news
FX Action: USD-CAD has nudged back above 1.3300 »

FX Action: USD-CAD has…

PRDSY

Prada

$0.00

(0.00%)

08:34
01/21/19
01/21
08:34
01/21/19
08:34
Upgrade
Prada rating change  »

Prada upgraded to Neutral…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

PANDY

Pandora A/S

$0.00

(0.00%)

08:33
01/21/19
01/21
08:33
01/21/19
08:33
Downgrade
Pandora A/S rating change  »

Pandora A/S downgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

SLGGF

SolGold

$0.00

(0.00%)

08:32
01/21/19
01/21
08:32
01/21/19
08:32
Initiation
SolGold initiated  »

SolGold initiated with an…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

PCFBY

Pacific Basin Shipping

$0.00

(0.00%)

08:30
01/21/19
01/21
08:30
01/21/19
08:30
Upgrade
Pacific Basin Shipping rating change  »

Pacific Basin Shipping…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

08:30
01/21/19
01/21
08:30
01/21/19
08:30
General news
Oil Action: Front-month WTI futures are near flat »

Oil Action: Front-month…

WFAFY

Wesfarmers

$0.00

(0.00%)

08:27
01/21/19
01/21
08:27
01/21/19
08:27
Downgrade
Wesfarmers rating change  »

Wesfarmers downgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

RTOKY

Rentokil

$0.00

(0.00%)

08:26
01/21/19
01/21
08:26
01/21/19
08:26
Downgrade
Rentokil rating change  »

Rentokil downgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

BNTGY

Brenntag

$0.00

(0.00%)

08:25
01/21/19
01/21
08:25
01/21/19
08:25
Upgrade
Brenntag rating change  »

Brenntag upgraded to Buy…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

08:25
01/21/19
01/21
08:25
01/21/19
08:25
General news
Oil Action: Front-month WTI futures are near flat »

Oil Action: Front-month…

LOIMF

Loomis AB

$0.00

(0.00%)

08:24
01/21/19
01/21
08:24
01/21/19
08:24
Downgrade
Loomis AB rating change  »

Loomis AB downgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

SFTBY

SoftBank; also use SFTBF

$0.00

(0.00%)

08:21
01/21/19
01/21
08:21
01/21/19
08:21
Initiation
SoftBank; also use SFTBF initiated  »

SoftBank initiated with a…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

07:00
01/21/19
01/21
07:00
01/21/19
07:00
General news
FX Update: There hasn't been a strong theme »

FX Update: There…

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.